logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Kalobios Pharmaceuticals, Inc.


USPTO Granted Patents = 19

% Expired Patents = 57.9


Trademarks = 1

Forward Citations = 65

Loading Chart...
Loading Chart...

18 inventors (with patents filed for the assignee):

goldMedal Christopher Robert Bebbington (16 out of 44 patents)

silverMedal Geoffrey T Yarranton (16 out of 28 patents)

bronzeMedal Kenneth Luehrsen (8 out of 10 patents)

4.  Mark Baer (4 out of 7 patents)

5.  Varghese Palath (4 out of 4 patents)

6.  David Martinez (3 out of 3 patents)

7.  Jeng-Horng Her (3 out of 15 patents)

8.  Robert F Balint (3 out of 6 patents)

9.  Christina Yi (2 out of 2 patents)

10.  Peter Flynn (1 out of 10 patents)

11.  Nenad Tomasevic (1 out of 10 patents)

12.  Bo Yu (1 out of 18 patents)

13.  Martin Lackmann (1 out of 4 patents)

14.  Jason Williams (1 out of 2 patents)

15.  Andrew Ewart Scott (1 out of 11 patents)


19 patents:

1. 9290571 - Antibodies to EphA3 (2016-03-22),
2. 9127046 - Secretion of antibodies without signal peptides from bacteria (2015-09-08),
3. 9109032 - Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow (2015-08-18),
4. 9045539 - Anti-EMR1 antibodies (2015-06-02),
5. 9017674 - Antibodies to granulocyte-macrophage colony-stimulating factor (2015-04-28),
6. 8877191 - [object Object] (2014-11-04),
7. 8834870 - Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 (2014-09-16),
8. 8664365 - Antibodies to EphA3 (2014-03-04),
9. 8642039 - [object Object] (2014-02-04),
10. 8637016 - EphA3 antibodies for the treatment of solid tumors (2014-01-28),
11. 8398972 - Methods of treating dementia using a GM-CSF antagonist (2013-03-19),
12. 8354251 - Transactivation system for mammalian cells (2013-01-15),
13. 8211648 - Secretion of antibodies without signal peptides from bacteria (2012-07-03),
14. 8168183 - Antibodies to granulocyte-macrophage colony-stimulating factor (2012-05-01),
15. 8075885 - Methods of treating heart failure using an anti-GM-CSF antibody (2011-12-13),
Company Overview
Kalobios Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for serious diseases. The company specializes in monoclonal antibodies and other biologics, aiming to address unmet medical needs in areas such as oncology and infectious diseases. Kalobios leverages advanced research methodologies and technology platforms to create targeted treatments, enhancing patient outcomes and advancing the field of medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#68 in South San Francisco, CA

#4,099 in California

#17,138 in US

#32,663 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Kalobios Pharmaceuticals, Inc.

Forward Citations = 65

18 inventors:

goldMedal Christopher Robert Bebbington (16 out of 44 patents)

silverMedal Geoffrey T Yarranton (16 out of 28 patents)

bronzeMedal Kenneth Luehrsen (8 out of 10 patents)

4.  Mark Baer (4 out of 7 patents)

5.  Varghese Palath (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kalobios Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/kalobios-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…